Morgan Stanley’s Boundless Bio BOLD Stock Holding History

Morgan Stanley’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.5K	Hold	13,000	–	–	﹤0.01%	6650
2026 Q1	$14.3K	Hold	13,000	–	–	﹤0.01%	6843
2025 Q4	$15.6K	Sell	13,000 -2,501	-16%	-$3.12K	﹤0.01%	6774
2025 Q3	$19.1K	Sell	15,501 -1,238	-7%	-$1.43K	﹤0.01%	6702
2025 Q2	$16.9K	Sell	16,739 -19,367	-54%	-$25.7K	﹤0.01%	6700
2025 Q1	$54.5K	Sell	36,106 -12,550	-26%	-$26K	﹤0.01%	6245
2024 Q4	$141K	Buy	48,656 +18,715	+63%	+$54.5K	﹤0.01%	5921
2024 Q3	$104K	Sell	29,941 -156,991	-84%	-$569K	﹤0.01%	5994
2024 Q2	$723K	Buy	+186,932	New	+$1.79M	﹤0.01%	5133

Other funds holding BOLD

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Morgan Stanley's BOLD Position: Q2 2026 in Review

Morgan Stanley held its Boundless Bio (BOLD) position steady in Q2 2026 at 13,000 shares worth $32.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6650.

Morgan Stanley first reported a position in BOLD in Q2 2024 and has held it in 9 quarters since. The position peaked at $723K in Q2 2024. 40 funds tracked by Wall St. Rank hold BOLD as of Q2 2026.

Morgan Stanley held 13,000 shares of Boundless Bio worth $32.5K as of Q2 2026.
Morgan Stanley left its Boundless Bio share count unchanged in Q2 2026.
Boundless Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6650 holding.
Morgan Stanley first reported a position in Boundless Bio in Q2 2024 and has held it in 9 quarters since.
Morgan Stanley's Boundless Bio position peaked at $723K in Q2 2024.
40 funds tracked by Wall St. Rank held Boundless Bio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.